Bayer
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Bayer sits in the top decile of US sponsors by registered trial count (#58 of 15,742 sponsors by registered trial count).
591 total trials 21 currently recruiting 494 completed top decile by trial count
Bayer: 591 sponsored US clinical trials, 21 recruiting.
Bayer sponsors 591 registered US clinical trials on ClinicalTrials.gov, 21 of them currently recruiting, and 494 completed. 172 of these trials are in Phase 3-4 (later-stage) and 237 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sunscreening Agents, with 17 trials.
Top-decile sponsor footprint
Bayer ranks in the top decile of sponsors by registered trial count (#58 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
D 63/100
494 of 552 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
591 total, page 1 of 12
RECRUITING
A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications
NCT07330258
RECRUITING
A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide
NCT07672119
RECRUITING Phase 3
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952
RECRUITING Phase 1
A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirin in Healthy Participants
NCT07652723
RECRUITING Phase 1
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
NCT07535112
RECRUITING Phase 3
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
NCT06904274
RECRUITING Phase 3
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07188805
RECRUITING Phase 2
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685
RECRUITING
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
NCT07406282
RECRUITING
An Observational Study to Learn More About Vasomotor Symptoms Burden and Treatment Patterns in Menopausal Women Before and After Participating in OASIS Studies
NCT06949553
RECRUITING Phase 1
A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
NCT06914128
RECRUITING Phase 1
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
NCT06764316
RECRUITING Phase 2
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819
RECRUITING Phase 3
A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277
RECRUITING
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
NCT06278207
RECRUITING Phase 1
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06217822
RECRUITING
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
NCT06117891
RECRUITING Phase 3
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283
RECRUITING Phase 3
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
NCT05196035
RECRUITING Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226
RECRUITING
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
NCT04142437
ACTIVE NOT RECRUITING
An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related
NCT06765681
ACTIVE NOT RECRUITING
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States
NCT06608212
ACTIVE NOT RECRUITING Phase 2
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
NCT06522997
ACTIVE NOT RECRUITING
An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States
NCT06272942
ACTIVE NOT RECRUITING Phase 1
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06052306
ACTIVE NOT RECRUITING Phase 3
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906
ACTIVE NOT RECRUITING Phase 1
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
NCT05614102
ACTIVE NOT RECRUITING Phase 1
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
NCT05537740
ACTIVE NOT RECRUITING
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
NCT05348733
ACTIVE NOT RECRUITING Phase 2
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.
NCT05059236
ACTIVE NOT RECRUITING Phase 1
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
NCT05099172
ACTIVE NOT RECRUITING
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
NCT04122976
ACTIVE NOT RECRUITING
Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
NCT03932201
ACTIVE NOT RECRUITING Phase 1
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"
NCT03588299
ACTIVE NOT RECRUITING Phase 1
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
NCT02637687
NOT YET RECRUITING
An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
NCT05477953
NOT YET RECRUITING
An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms in United States
NCT07490431
NOT YET RECRUITING Phase 2
A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
NCT07625215
COMPLETED Phase 1
A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose
NCT07102095
COMPLETED
An Observational Study to Learn More About How Menopause Affects Women's Sleep and How They Are Being Treated for Sleep Problems
NCT06728332
COMPLETED Phase 1
A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years
NCT06562985
COMPLETED Phase 1
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
NCT06345001
COMPLETED Phase 1
A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants
NCT06511973
COMPLETED Phase 1
A Study to Learn About Whether BAY H006689 Causes an Allergic Reaction When Applied as a Topical Gel in Healthy Participants
NCT06415019
COMPLETED Phase 1
A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function
NCT06402721
COMPLETED Phase 2
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
NCT06195930
COMPLETED Phase 1
A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants
NCT06360211
COMPLETED
An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States
NCT06363110
COMPLETED Phase 1
A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants
NCT06348888
Page 1 of 12 Next →
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 130 |
| Phase 2 | 107 |
| Phase 3 | 144 |
| Phase 4 | 28 |
What is open in the Bayer pipeline
21 recruiting of 591 indexed (4% open); 494 completed (84%).
Phase mix: 172 late (III/IV) vs 237 early (I/II) (balanced across stages).
Top condition: Sunscreening Agents (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bayer: open-pipeline peers nationwide
Peers matched on 591 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Bayer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 591 trials (± recruiting share)
- Janssen Research & Development · 593 trials · 11% recruiting
- City of Hope Medical Center · 582 trials · 29% recruiting
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Bausch Health Americas · 4% recruiting · 168 trials
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Sumitomo Pharma America · 4% recruiting · 168 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
Related
Read our methodology
- how this data is sourced, computed, and verified.
What to do with this Bayer page
591 registered trials is a research-attention snapshot, not an endorsement of Bayer or any single study.
- 21 of Bayer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Sunscreening Agents is the condition Bayer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sunscreening Agents trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Bayer pipeline card: 591 registered trials from official public datasets.Report a data error.